Skip to main content

United StatesBreaking News

Grafa

Tenaya Therapeutics reports positive data from RIDGE-1 Phase 1b/2 trial of TN-401 in PKP2-associated ARVC

Tenaya Therapeutics (NASDAQ:TNYA), a clinical-stage biotechnology company developing gene therapies for heart disease, reported positive interim data from the first two cohorts of its ongoing RIDGE-1 Phase 1b/2 trial of TN-401 in patients with PKP2-associated arrhythmogenic right ventricular cardiomyopathy (ARVC).

Read more